Document is current
Any future updates will be listed below
-
Authors
Lebwohl, Mark G. https://orcid.org/0000-0002-4705-5303
Koo, John Y. https://orcid.org/0009-0004-1005-5221
Armstrong, April W. https://orcid.org/0000-0002-6892-6286
Strober, Bruce E. https://orcid.org/0000-0002-8394-2057
Yoon, Soo Han https://orcid.org/0000-0003-3685-668X
Rawnsley, Nicole N. https://orcid.org/0009-0005-7856-6615
Goehring, Earl L. Jr https://orcid.org/0000-0002-3935-8355
Mangin, Gina D.
Jacobson, Abby A. https://orcid.org/0000-0002-7810-2280
-
Funding
Funding for this research was provided by:
Ortho Dermatologics
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 25 October 2024
First Online: 26 November 2024
Declarations
:
: Mark G. Lebwohl is an employee of Mount Sinai; receives research funds from AbbVie, Arcutis Biotherapeutics, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy Dermatology, Strata, Takeda, Trevi Therapeutics, and Verrica. John Y. Koo has been a consultant or speaker for AbbVie, Amgen, Eli Lilly, EPI, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and Sun Pharmaceutical. April W. Armstrong has served as a research investigator for and/or scientific advisor to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Dermira, Eli Lilly, EPI, Incyte, Janssen, LEO Pharma, Mindera, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical, and UCB. Bruce E. Strober has been an investigator, scientific director, consultant, or member of a speakers bureau or advisory board for AbbVie, Acelyrin, Alamar, Almirall, Alumis, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol-Myers-Squibb, Capital One, Celltrion, CorEvitas and the CorEvitas Psoriasis Patient Registry, Dermavant, Inmagenebio, Incyte, Janssen, Leo, Eli Lilly, Kangpu Pharmaceuticals, Maruho, Okura, Meiji Seika Pharma, Protagonist, Monte Carlo, Takeda, Novartis, Pfizer, UCB Pharma, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, Union Therapeutics; holds stock options in Connect Biopharma and Mindera Health; and serves as the editor-in-chief of the Journal of Psoriasis and Psoriatic Arthritis. Soo Han Yoon is an employee of Salix Pharmaceuticals. Gina D. Mangin has been a speaker for AbbVie, Dermavant, and Sanofi-Regeneron and a consultant for Amgen, Arcutis Biotherapeutics, Bristol-Myers Squibb, Eli Lilly, Incyte, Janssen, and LEO Pharma. Nicole N. Rawnsley, Earl L. Goehring Jr, and Abby A. Jacobson are employees of Bausch Health Companies Inc.
: Ethics approval and informed consent were not required, as the post-marketing data summarized in this report were noninterventional and were not collected as part of a clinical study.
